What does Immunxperts do?
ImmunXperts specializes in the development of innovative immunotherapies aimed at treating various diseases, including cancer. The company focuses on harnessing the immune system's power to enhance patient outcomes through advanced research and clinical trials. Their expertise encompasses a range of technologies, including monoclonal antibodies and personalized medicine approaches.
- Signals
-
Negative equityNegative equity € -1.60M
Equity is negative: debts exceed assets (technically insolvent).
Reporting lossesReporting losses € -2.66MThe company reported a loss in the latest financial year.
Poor liquidityPoor liquidity 0.45The current ratio is below 1: may be insufficient to cover short-term debt.
Negative cashflowNegative cashflow € -2.10MOperating cash flow was negative in the latest financial year.
Negative EBITDANegative EBITDA € -1.79MEBITDA is negative: operating activities are loss-making.
High social debt vs. personnel costsHigh social debt vs. personnel costs 29.0%Social debts are a high share of personnel costs, which may indicate social security arrears.
Financial ratios
|
max) max = w;
}
}
const wClamped = Math.max(120, Math.min(800, max));
colWidths[''] = wClamped;
save && save();
})(event)">
|
2024
max) max = w;
}
}
const wClamped = Math.max(120, Math.min(800, max));
colWidths[''] = wClamped;
save && save();
})(event)">
|
2023
max) max = w;
}
}
const wClamped = Math.max(120, Math.min(800, max));
colWidths[''] = wClamped;
save && save();
})(event)">
|
2022
max) max = w;
}
}
const wClamped = Math.max(120, Math.min(800, max));
colWidths[''] = wClamped;
save && save();
})(event)">
|
2021
max) max = w;
}
}
const wClamped = Math.max(120, Math.min(800, max));
colWidths[''] = wClamped;
save && save();
})(event)">
|
|---|---|---|---|---|
|
€
393K
|
€
2.56M
|
€
2.75M
|
€
2.43M
|
|
|
€
-1.79M
|
€
270K
|
€
1.01M
|
€
658K
|
|
|
€
-2.98M
|
€
-266K
|
€
458K
|
€
238K
|
|
|
€
-1.60M
|
€
1.40M
|
€
1.77M
|
€
1.45M
|
|
|
-16.72%
|
12.95%
|
26.53%
|
27.53%
|
|
|
€
11.18M
|
€
9.44M
|
€
4.89M
|
€
3.83M
|
|
|
€
1.51M
|
€
1.78M
|
€
605K
|
€
564K
|
|
|
25.80
|
26.70
|
20.10
|
20.10
|
Publications 17
All publications- Siege Social 02/02/2024
- Demissions, Nominations 04/05/2023
- Demissions, Nominations 14/02/2023
- Demissions, Nominations 31/05/2022
- Demissions, Nominations 14/04/2021
Frequently asked questions
Answers to the most common questions about Immunxperts, based on official government data and the filed annual accounts.
What is the VAT number of Immunxperts?
The VAT number of Immunxperts is BE0552.755.587.
How many employees work at Immunxperts?
In 2024, Immunxperts employed 25.80 full-time equivalents (FTE).
When was Immunxperts established?
Immunxperts was founded in 16-05-2014.
What is the official address of Immunxperts?
The official address of Immunxperts is Rue Clément Ader 10 Charleroi 6041.
What is the legal form of Immunxperts?
The juridical form of Immunxperts is Public limited company (NV/SA).
What is the annual revenue of Immunxperts?
The 2024 accounts of Immunxperts do not report revenue. Smaller companies that file abbreviated accounts are not required to publish it.
What does Immunxperts do?
ImmunXperts specializes in the development of innovative immunotherapies aimed at treating various diseases, including cancer. The company focuses on harnessing the immune system's power to enhance patient outcomes through advanced research and clinical trials. Their expertise encompasses a range of technologies, including monoclonal antibodies and personalized medicine approaches.
Is Immunxperts a reliable company?
Immunxperts is a registered Rechtspersoon with company number 0552.755.587 and can be verified through the official CBE database.
What is the credit limit of Immunxperts?
The estimated credit limit of Immunxperts is €0.
Is Immunxperts still active?
Immunxperts currently has the status "Normal situation" and is active.